TY - JOUR
T1 - Barriers to Behavioral Treatment Adherence for Headache
T2 - An Examination of Attitudes, Beliefs, and Psychiatric Factors
AU - Matsuzawa, Yuka
AU - Lee, Yuen Shan Christine
AU - Fraser, Felicia
AU - Langenbahn, Donna
AU - Shallcross, Amanda
AU - Powers, Scott
AU - Lipton, Richard
AU - Simon, Naomi
AU - Minen, Mia
N1 - Funding Information:
Funding: No funding. Dr. Minen is a recipient of the AAN-ABF Practice Research Training Fellowship, the ECRIP grant, and an NIH K23 grant (AT009706-01), which funds her time to conduct research.
Funding Information:
Conflict of Interest: Dr. Yuka Matsuzawa, Dr. Yuen Shan Christine Lee, Dr. Felicia Fraser, Dr. Donna Langenbahn, Dr. Amanda Shallcross, Dr. Scott Powers, and Dr. Naomi Simon: No conflicts of interest. Dr. Richard B. Lipton receives support from the Migraine Research Foundation and the National Headache Foundation. He holds stock options in eNeura Therapeutics; serves as consultant, advisory board member, or has received honoraria from: Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Boston Scientific, Colucid, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, Glaxo, Inc., Merck, GlaxoSmithKline (formerly Novartis), Pfizer, Teva, and Vedanta. He receives royalties from Wolff’s Headache, 8th Edition, Oxford Press University, 2009 and Informa. Dr. Mia Minen is a recipient of the AAn-ABF Practice Research Training Fellowship, the ECRIP grant, and a NIH K23 grant (AT009706-01) which pays for time to conduct research.
Publisher Copyright:
© 2018 American Headache Society
PY - 2019/1
Y1 - 2019/1
N2 - Background/Objectives: Nonpharmacological interventions, such as biofeedback, cognitive behavioral therapy, and relaxation techniques are Level-A evidence-based treatments for headache. The impact of these interventions is often equivalent to or greater than pharmacological interventions, with fewer side effects. Despite such evidence, the rate of participation in nonpharmacological interventions for headache remains low. Once obstacles to optimizing use of behavioral interventions, such as local access to nonpharmacological treatment and primary headache providers are traversed, identification of barriers contributing to low adherence is imperative given the high levels of disability and cost associated with treating headache disorders. In this review of factors in adults associated with underuse of nonpharmacological interventions, we discuss psychological factors relevant to participation in nonpharmacological treatment, including attitudes and beliefs, motivation for change, awareness of triggers, locus of control, self-efficacy, acceptance, coping styles, personality traits, and psychiatric comorbidities associated with treatment adherence. Finally, future prospects and approaches to optimizing treatment matching and minimizing adherence issues are addressed. Methods: An interdisciplinary team conducted this narrative review. Neuropsychologists conducted a literature search during the month of July 2017 using a combination of the keywords (“headache” or “migraine”) and (“adherence” or “compliance”) or “barriers to treatment” or various “psychological factors” discussed in this narrative review. Content experts, a psychiatrist, and a complementary and integrative health specialist provided additional commentary and input to this narrative review resulting in integration of additional noteworthy studies, book chapters and books. Results: Various psychological factors, such as attitudes and beliefs, lack of motivation, poor awareness of triggers, external locus of control, poor self-efficacy, low levels of acceptance, and engagement in maladaptive coping styles can contribute to nonadherence. Conclusions: To maximize adherence, clinicians can assess and address an individual’s level of treatment acceptance, beliefs that may present as barriers, readiness for change, locus of control, self-efficacy and psychiatric comorbidities. Identification of barriers to adherence as well as the application of relevant assessment and intervention techniques have the potential to facilitate adherence and ultimately improve treatment success.
AB - Background/Objectives: Nonpharmacological interventions, such as biofeedback, cognitive behavioral therapy, and relaxation techniques are Level-A evidence-based treatments for headache. The impact of these interventions is often equivalent to or greater than pharmacological interventions, with fewer side effects. Despite such evidence, the rate of participation in nonpharmacological interventions for headache remains low. Once obstacles to optimizing use of behavioral interventions, such as local access to nonpharmacological treatment and primary headache providers are traversed, identification of barriers contributing to low adherence is imperative given the high levels of disability and cost associated with treating headache disorders. In this review of factors in adults associated with underuse of nonpharmacological interventions, we discuss psychological factors relevant to participation in nonpharmacological treatment, including attitudes and beliefs, motivation for change, awareness of triggers, locus of control, self-efficacy, acceptance, coping styles, personality traits, and psychiatric comorbidities associated with treatment adherence. Finally, future prospects and approaches to optimizing treatment matching and minimizing adherence issues are addressed. Methods: An interdisciplinary team conducted this narrative review. Neuropsychologists conducted a literature search during the month of July 2017 using a combination of the keywords (“headache” or “migraine”) and (“adherence” or “compliance”) or “barriers to treatment” or various “psychological factors” discussed in this narrative review. Content experts, a psychiatrist, and a complementary and integrative health specialist provided additional commentary and input to this narrative review resulting in integration of additional noteworthy studies, book chapters and books. Results: Various psychological factors, such as attitudes and beliefs, lack of motivation, poor awareness of triggers, external locus of control, poor self-efficacy, low levels of acceptance, and engagement in maladaptive coping styles can contribute to nonadherence. Conclusions: To maximize adherence, clinicians can assess and address an individual’s level of treatment acceptance, beliefs that may present as barriers, readiness for change, locus of control, self-efficacy and psychiatric comorbidities. Identification of barriers to adherence as well as the application of relevant assessment and intervention techniques have the potential to facilitate adherence and ultimately improve treatment success.
KW - barriers to adherence
KW - headache
KW - nonpharmacological interventions
KW - psychological factors
UR - http://www.scopus.com/inward/record.url?scp=85055471610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055471610&partnerID=8YFLogxK
U2 - 10.1111/head.13429
DO - 10.1111/head.13429
M3 - Review article
C2 - 30367821
AN - SCOPUS:85055471610
SN - 0017-8748
VL - 59
SP - 19
EP - 31
JO - Headache
JF - Headache
IS - 1
ER -